Ignite Creation Date:
2024-05-06 @ 6:41 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05751265
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-06-22
First Post:
2023-02-21
Brief Title:
Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer
Sponsor:
Fujian Cancer Hospital
Organization:
Fujian Cancer Hospital
Organization Data
Organization:
Fujian Cancer Hospital
Class:
OTHER_GOV
Study ID:
GC-01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Fujian Cancer Hospital
Lead Sponsor Class:
OTHER_GOV
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None